RESULTS	Mesalazine enema was found to reduce the probability of impairment at week 4 for mobility ( p = 0.049 ) and anxiety/depression ( p = 0.048 ) , and was of borderline significance for pain/discomfort ( p = 0.053 ) ; there was also an increased probability of influencing HRQoL changes for mobility ( p < 0.005 ) , usual activities ( p < 0.005 ) , pain/discomfort ( p < 0.005 ) and anxiety/depression ( p < 0.005 ) , based on reported HRQoL problems at baseline .\